Sonidegib Therapeutic Cheat Sheet
Basal cell carcinoma (BCC) is the most common human cancer. When curative surgery and radiotherapy are contraindicated, systemic agents targeting the hedgehog signaling pathway are invaluable options for this subset of adult patients with locally advanced BCC (laBCC). Vismodegib and sonidegib are oral options with similar efficacy and side effect profiles. With the absence of head-to-head comparis …
Basal cell carcinoma (BCC) is the most common human cancer. When curative surgery and radiotherapy are contraindicated, systemic agents targeting the hedgehog signaling pathway are invaluable options for this subset of adult patients with locally advanced BCC (laBCC). Vismodegib and sonidegib are oral options with similar efficacy and side effect profiles. With the absence of head-to-head comparis … 
At the 2024 ODAC Dermatology, Aesthetic & Surgical Conference, we were lucky to learn about the management of chronic spontaneous urticaria (CSU) from the renowned researcher and clinician, Dr. Adam J. Friedman, Professor and Chair of Dermatology at The George Washington University School of Medicine and Health Sciences. CSU can be a frustrating, exhausting condition for patients to endure, wi … 
Dr. Adam Friedman's lecture at 2024 ODAC conference provided invaluable insights into the nuanced approach required when dealing with patients presenting with alopecia. Addressing the diverse array of alopecia types and their myriad presentations, Dr. Friedman emphasized the significance of a comprehensive clinical history and evaluation to formulate an effective treatment plan. By employing a cas … 
The path to becoming a dermatologist is challenging—from years of school, residency, research to ultimately creating a career. But post-residency paralysis could prevent you from knowing what to do with your career. Instead, hear from our experts at ODAC 2023 on general advice for your next steps following residency and more specific pathways, including:
Academic Dermatology
Fellow … 
Apremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica … 